首页> 美国卫生研究院文献>Oncology Letters >CRM1 a novel independent prognostic factor overexpressed in invasive breast carcinoma of poor prognosis
【2h】

CRM1 a novel independent prognostic factor overexpressed in invasive breast carcinoma of poor prognosis

机译:CRM1一种在预后不良的浸润性乳腺癌中过表达的新型独立预后因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Breast cancer (BC) is the most commonly diagnosed cancer in females globally and is more aggressive at later stages. Chromosome region maintenance 1 (CRM1) is involved in the nuclear export of proteins and RNAs and has been associated with a number of malignancies. However, the clinicopathological significance of its expression in BC remains to be elucidated therefore this was investigated in the present study. CRM1 expression in 280 breast cancer tissues and 60 normal tissues was retrospectively analyzed using immunohistochemistry (IHC) and western blotting. IHC investigation demonstrated that CRM1 expression was significantly increased in BC compared with the normal breast epithelium (P<0.0001). Overexpression of CRM1 was markedly associated with poor prognostic characteristics, including larger tumor size (P=0.024), positive lymph node metastasis (P=0.032), invasive histological type (P=0.004) and distant metastasis (P=0.026). Significant associations were also observed between increased CRM1 expression and the progesterone receptor (P=0.028) and Ki67 (P=0.019). Kaplan-Meier survival analysis demonstrated that patients with high CRM1 expression exhibited a reduced disease-free survival and overall survival compared with those with low CRM1 expression (P=0.013). In the multivariate analysis, CRM1 expression (P=0.011), tumor size (P=0.001) and lymph node metastasis (P<0.001) were independent prognostic markers of BC. In conclusion, CRM1 serves an important role in BC and may serve as a predictive and prognostic factor for a poor outcome in patients with BC.
机译:乳腺癌(BC)是全球女性中最常被诊断出的癌症,并且在以后的阶段更具侵略性。染色体区域维持1(CRM1)参与蛋白质和RNA的核输出,并与许多恶性肿瘤有关。然而,其在BC中表达的临床病理学意义尚待阐明,因此在本研究中对此进行了研究。使用免疫组织化学(IHC)和蛋白质印迹技术回顾性分析了280个乳腺癌组织和60个正常组织中的CRM1表达。 IHC研究表明,与正常乳腺上皮相比,BC中CRM1的表达显着增加(P <0.0001)。 CRM1的过表达与不良的预后特征显着相关,包括较大的肿瘤大小(P = 0.024),淋巴结转移阳性(P = 0.032),浸润性组织学类型(P = 0.004)和远处转移(P = 0.026)。还观察到CRM1表达增加与孕激素受体(P = 0.028)和Ki67(P = 0.019)之间存在显着关联。 Kaplan-Meier生存分析表明,与低CRM1表达的患者相比,高CRM1表达的患者表现出降低的无病生存期和总生存期(P = 0.013)。在多变量分析中,CRM1表达(P = 0.011),肿瘤大小(P = 0.001)和淋巴结转移(P <0.001)是BC的独立预后指标。总之,CRM1在BC中起着重要作用,并且可以作为BC患者预后不良的预测和预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号